Company News & Announcements

May 16, 2011

Xanodyne Pharmaceuticals Appoints New Chief Operating Officer

May 27, 2010

XANODYNE ANNOUNCES PLANNED PRESIDENT & CEO SUCCESSION

May 7, 2010

XANODYNE ANNOUNCES RENEWED FOCUS ON PAIN MANAGEMENT MARKET

[ Corporate Governance ]

Xanodyne

Welcome to Xanodyne

Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management. We market a portfolio of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in pain management.

Product Withdrawal: Xanodyne agrees to withdraw Propoxyphene from US market.

Recently Approved: Zipsor^® for the treatment of mild to moderate acute pain in adults was approved by the FDA on June 16, 2009.

We are Developing: XP21B for the treatment of acute pain is in Phase 2 development.

Product Highlights

Zipsor^®

Zipsor^® is the first liquid filled capsule NSAID with ProSorb^® technology indicated for mild to moderate acute pain in adults (18 years or older)... [MORE]

Zipsor^®

Zipsor^® is the first liquid filled capsule NSAID with ProSorb^® technology indicated for mild to moderate acute pain in adults (18 years or older)... [MORE]

Zipsor^®

Zipsor^® is the first liquid filled capsule NSAID with ProSorb^® technology indicated for mild to moderate acute pain in adults (18 years or older)... [MORE]